

	<b>Overall Population</b> (N=209)		<b>No Surgery</b> (N=137)		<b>Surgery</b> (N=72)		<b>p</b>
<b>Age at diagnosis, median (IQR)</b>	53.1	(46.9 - 59.3)	53.8	(47.6 - 59.4)	51.3	(44.4 - 58.8)	0.25
<b>Type of BRCA mutation, n (%)</b>							0.33
BRCA 1	143	(68.4)	96	(70.1)	47	(65.3)	
BRCA 2	65	(31.1)	41	(29.9)	24	(33.3)	
Both BRCA 1/ 2	1	(0.5)	0	(0.0)	1	(1.4)	
<b>FIGO stage, n (%)</b>							0.17
I	11	(5.3)	7	(5.1)	4	(5.6)	
II	12	(5.7)	11	(8.0)	1	(1.4)	
III	163	(78.0)	102	(74.5)	61	(84.7)	
IV	23	(11.0)	17	(12.4)	6	(8.3)	
<b>Bevacizumab as maintenance, n (%)</b>							0.38
No	119	(56.9)	75	(54.7)	44	(61.1)	
Yes	90	(43.1)	62	(45.3)	28	(38.9)	
<b>Residual Tumor at First Surgery, n (%)</b>							0.06
RT=0	129	(61.7)	77	(56.2)	52	(72.2)	
RT<1	42	(20.1)	30	(21.9)	12	(16.7)	
RT≥1	38	(18.2)	30	(21.9)	8	(11.1)	

IQR: Interquantile Range; RT: Residual Tumor

**Table 1 supplementary.** Patients' Clinical - Pathological characteristics at diagnosis.


	<b>PFS</b>		
	<b>HR</b>	<b>(95% CI)</b>	<b>p value</b>
<b>Surgery</b>	0.22	(0.08 – 0.55)	0.001
<b>Age at diagnosis</b>	1.01	(0.97 – 1.06)	0.437
<b>ECOG PS</b>	1.74	(0.62 – 4.92)	0.290
<b>BRCA</b>	0.62	(0.28 – 1.33)	0.223
<b>Residual Tumor at First Surgery</b>	1.27	(0.84 – 1.93)	0.250
<b>Bevacizumab as maintenance</b>	1.73	(0.78 – 3.82)	0.170

**Table 2 supplementary.** Inclusion of patients who had received only one previous line of treatment (n=93).

	PFS		
	HR	(95% CI)	p value
Surgery	0.21	(0.84 – 0.53)	0.001
Age at diagnosis	1.02	(0.96 – 1.07)	0.432
ECOG PS	1.56	(0.50 – 4.83)	0.435
BRCA	0.80	(0.33 – 1.93)	0.632
Residual Tumor at First Surgery	1.39	(0.87 – 2.22)	0.158
Bevacizumab as maintenance	1.56	(0.61 – 3.94)	0.346

**Table 3 supplementary.** Exclusion of centers where secondary surgery was not performed or it was performed in all patients enrolled and of patients who have received more than one previous line of therapy (n=71).

**Figure 1 supplementary.** Flowchart of included patients.



**Figure 2 supplementary.** Progression Free Survival according to BRCA mutational status: BRCA 2 mutated patients showed a better prognosis when compared to BRCA 1 carriers (Log rank=0.0498).

